New hope for lung cancer that morphs after targeted therapy: combo drug trial launches
Disease control
Recruiting now
This study tests a new drug, tarlatamab, combined with standard chemotherapy and immunotherapy for people whose lung cancer has changed from one type to another (from adenocarcinoma to small cell lung cancer) after initial targeted treatment. About 50 adults whose cancer has not …
Phase: PHASE2 • Sponsor: Se-Hoon Lee • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC